Optimax Holdings Bhd’s (OPTIMAX) 1Q23 core net profit advanced 17.9% YoY to RM3.1m. Although the earnings amounted to 20.0% of our full year forecast of RM15.5m, and 17.3% of consensus of RM18.0m, we deemed it is broadly in line as typically the 1Q will be softer due to lower surgeries done during festive season such as Chinese New Year.
YoY, the increase in core net profit stemmed from (i) increase in number of refractive and cataract surgeries across all ambulatory care centres (ACC) and satellite clinics, (ii) higher contribution from the newly set up satellite clinic, and (iii) ongoing promotions for eye specialist services through online platforms.
However, Optimax saw a slight decrease in profit before tax margin, due to additional staffs hired in advance for the upcoming expansion of the new ACC and satellite clinics. The impact is expected to be diminished upon the operationalization of the new ACC and satellite clinics.
QoQ, core net profit declined 20.4% to RM3.1m, owing to the decrease in revenue resulted from lower number of refractive and cataract surgeries conducted during 1Q23 as people tend to do surgery after the festive season such as Chinese New Year. As such, we expect the revenue will rebound in the forthcoming quarters based on historical trend.
To date, Optimax has established a network of 13 ACCs, 3 satellite clinics, and 1 specialist hospital, spanning across all regions in Malaysia. Optimax remained committed to expand its presence and brand in Malaysia to cater to medical tourism, targeting to establish 5-7 additional satellite clinics in FY23. In the longer term, we envision new sources of revenue stemming from Kempas eye hospital and Setia Alam Hospital (where Optimax will operate a full-service eye specialist centre on an exclusive basis). Construction is underway for both facilities, with plans for both facilities to be fully operational by 2025.
Moving forward, we foresee an improvement in performance for Optimax’s branches in light of the World Health Organization’s (WHO) officially declaring an end to the Covid-19 as a public health emergency, coupled with heightened awareness amongst the general public with regards to the importance of eyecare.
Valuation & Recommendation
Since the earnings came in broadly within our expectations, we kept our forecast unchanged at RM15.5m and RM17.6m for FY23f and FY24f respectively, taking into account the expected increase in revenue in the forthcoming quarters.
We maintained our BUY recommendation on OPTIMAX with an unchanged target price of RM1.15. The target price is based on the assigned target PER of 40.0x to our revised FY23f EPS of 2.9 sen.
Risks to our recommendation include the risks of medical and legal claims related to the provision of its eye specialist services. Besides, the inflationary pressure due to rising food and energy prices remains as threat to local economy.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....